vra

[csco]

وسعر مناسب على 10سنت مااعتقد انها تنزل اكثر واذا نزلت سرعان ماتعود ولن تنزل كثيرا اخر حد 9سنت وذلك الوقت لن يبيع احد على 9 لذلك انصح بالشراء على 10 سنت واتمنى لكم التوفيق

[Pivotrend]

CSCO
أنت أول من صاد VRA ودبلت أكثر من 600% بيوم واحـد
تاريخ أنفجار VRA قبل سنه , كان 20-5-2003
عيد ميلاد سعيد , الآن 20-5-2004 أو يمكن تنفجر بعد كم يوم
;)

[الشعثاني]

-

:(

[Pivotrend]

not approved لحد الآن , وشكل السهم أكل هـوا :D

as well as for a reverse split of our common stock. A special meeting of our stockholder has been called for June 11, 2004 in order to solicit the required approvals.

[المبتدئ]

السلام عليكم....
اليوم حصلت السهم صل 1.40 ؟؟؟؟
ممكن اعرف السبب هل صار سبليت؟؟

[أبو محسن]

نعم اخي المبتدئ حصل له سبليت امس

1 : 10 Stock Split on 15-06-2004

[المبتدئ]

شكرا أخي الكريم ...

[أبو هشام]

هل تستحق المتابعة اليوم

عليها خبر
http://biz.yahoo.com/prnews/041005/fltu007_1.html
ما عندي معلومات عن الخبر لكن ربما تستحق الملاحظة اليوم ..

52wk Range: 0.83 - 3.50

أغلقت امس 1.12

[أبو هشام]

من عنده ياخوان خبرة و معلومات عن هذا الخبر عن نتائج البحث عن انوع معين من الأورام يعني هل الخبر يستاهل؟ الان السعر 1.21 وربما يستحسن الانتظار حتى نرى سعر الاغلاق اليوم

http://biz.yahoo.com/prnews/041005/fltu007_1.html

Viragen's Multiferon(R) Demonstrates Statistically Significant Increase in Overall Survival in Melanoma Study
Tuesday October 5, 9:15 am ET


PLANTATION, Fla., Oct. 5 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA - News) and its majority-owned subsidiary, Viragen International, Inc. (OTC Bulletin Board: VGNI - News), today announced the results from a 7-year follow- up to a Phase II/III clinical study that evaluated the use of Multiferon®, natural human alpha interferon, for the treatment of malignant melanoma after surgical removal of all tumor masses compared to surgery alone. The analysis confirmed a statistically significant increase in overall survival for patients treated with adjuvant dacarbazine (DTIC) followed by Multiferon®, compared to patients with no adjuvant treatment. The study data will serve as the basis for an application that Viragen intends to file in Sweden to seek expanded approval for Multiferon® to include the first-line adjuvant treatment of high-risk malignant melanoma.



After a 7-year follow-up, the results showed an actual 51.3% overall survival in high-risk patients treated with short-term DTIC, followed by Multiferon® as adjuvant low-dose treatment for 6 months versus 30.3% overall survival among patients who underwent surgery only (p=0.0077).

A follow-up beyond 7 years was obtained in most patients and 9-year follow-up results showed an estimated 50.9% overall survival in the treated population versus 23.5% in the control group. This suggests that a significant survival benefit is sustained beyond 7 years.

"We intend to submit an application for registration with the Swedish regulatory authorities for this new indication this year, which if approved, could provide us with the opportunity to proceed with Mutual Recognition Procedure (MRP) in the European Union (EU)," stated Viragen's President & CEO, Mr. Charles A. Rice. "This study is of paramount importance as part of our strategy to expand approvals for Multiferon® into major global markets, as well as enhance our ability to attract key strategic partners."

About the Phase II/III Malignant Melanoma Study:

In a controlled, randomized, multi-center trial conducted in Germany, the study evaluated the adjuvant sequential treatment of Malignant Melanoma (Stage IIb, IIIa, IIIb; high risk) with dacarbazine (DTIC) followed by Multiferon® (Highly purified, multi-subtype, natural human alpha interferon) versus untreated controls, in patients who underwent complete surgical removal of all tumor masses. The study was followed up for a minimum of 7 years in each individual patient.

In spite of the extremely promising outcome, it is ultimately the decision of the appropriate regulatory authorities as to whether or not the data is accepted for the basis of an approval.

ينتظرون ابروفال ؟؟؟

About Malignant Melanoma:

Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. About 132,000 people worldwide are diagnosed with melanoma each year, and more than 37,000 die from the disease annually. According to Decision Resources, current pharmaceutical therapies are extremely toxic and ineffective in the majority of patients. Any emerging therapy that can bring modest improvements in overall survival and tolerability will revolutionize the treatment of malignant melanoma.

Research and Markets reports that the worldwide melanoma therapeutics market is estimated at $265 million in 2004 and is expected to exceed $630 million worldwide by 2009.

About Alpha Interferon:

The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond. In some instances, recombinant interferon is rejected by the patient's immune system, possibly the result of the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side effects sometimes associated with recombinant therapy, especially when applied in such high doses as they are approved for melanoma treatment.

About Multiferon®:

Multiferon® is a highly purified, multi-subtype, natural human alpha interferon derived from human white blood cells and is approved in Sweden for the second-line treatment of any and all diseases in which patients show an initial response to recombinant alpha interferon followed by treatment failure, possibly due to the formation of neutralizing antibodies.

Multiferon® is also approved for sale in the following countries for the treatment of a range of viral and malignant diseases: Czech Republic, Egypt, Hong Kong, Indonesia, Mexico, Myanmar, South Africa and Thailand. Work is ongoing to expand the approved indications in these countries. Regulatory approval activities are also underway in a number of other European, South American, Middle East and Far East territories.

[الشعثاني]

Viragen Reports Increased Demand for Multiferon in Mexico


http://biz.yahoo.com/prnews/041014/flth015_1.html



LAST = 1.2